Medications not yet evaluated by P&T are considered NON-FORMULARY. Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step!
Please be sure to document all clinical activities daily.
Search results for:

sotrovimab

sotrovimab
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
sotrovimab INJECTION, INTRAVENOUS 500 mg/8 mL      
Comments:

Distribution of sotrovimab has been discontinued nationally due to the decreased efficacy of it with the now dominant SARS-CoV-2 Omicron BA.2 sub-variant.

 

Reviewed: June 2021 (Sotrovimab)

Updated: Feb. 2022 (Sotrovimab)

Updated: April 2022 (Sotrovimab)

Last updated: Apr. 26, 2023






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2026 Rpharmy, LLC ­ All Rights Reserved